MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss for the
period attributable to...
-$8,197,565
Net loss
attributable to...
-$80,763
Net loss for the
period
-$8,278,328
Financial income, net
$158,646
Operating loss
-$8,322,943
Change in fair value of
the warrant...
$69,201
Share of loss on equity
investment
-$44,830
Total operating
expenses
$8,322,943
Research and development
expenses
$6,683,643
General and
administrative expenses
$1,639,300
Back
Back
Income Statement
source: myfinsight.com
BriaCell Therapeutics Corp. (BCTX)
BriaCell Therapeutics Corp. (BCTX)